Drug Competition Act of 2002

Summary

Drug Competition Act of 2001 - Requires brand name drug manufacturers and generic drug manufacturers to file with the Federal Trade Commission and the Attorney General agreements affecting the sale or manufacture of generic drugs which could have the effect of limiting the research, development, manufacture, marketing, or selling of a generic drug product.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

11 official files

• Referred in House (text)

  Referred in House · EN · 19 November 2002

  ViewDownloadOpen at official source

• Referred in House (PDF)

  Referred in House · EN · 19 November 2002

  ViewDownloadOpen at official source

• Engrossed in Senate (text)

  Engrossed in Senate · EN · 18 November 2002

  ViewDownloadOpen at official source

• Engrossed in Senate (PDF)

  Engrossed in Senate · EN · 18 November 2002

  ViewDownloadOpen at official source

• Passed Senate amended

  summary · EN · 18 November 2002

  Open at official source

• Reported to Senate (text)

  Reported to Senate · EN · 20 June 2002

  ViewDownloadOpen at official source

• Reported to Senate (PDF)

  Reported to Senate · EN · 20 June 2002

  ViewDownloadOpen at official source

• Reported to Senate with amendment(s)

  summary · EN · 20 June 2002

  Open at official source

• Introduced in Senate (text)

  Introduced in Senate · EN · 6 April 2001

  ViewDownloadOpen at official source

• Introduced in Senate (PDF)

  Introduced in Senate · EN · 6 April 2001

  ViewDownloadOpen at official source

• Introduced in Senate

  summary · EN · 6 April 2001

  Open at official source

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.